Zura Bio Q1 net loss $24.2M ($0.22/sh); advancing tibulizumab Phase 2 trials

Zura Bio Ltd

2026-Q1 EPS reported -$0.22

Net loss of $24.2M ($0.22 per share) vs. $17.4M ($0.19) in Q1 2025.
R&D expenses $14.7M, up from $10.5M, driven by tibulizumab Phase 2 programs.
Cash $225.6M as of March 31, 2026, expected to fund operations through at least end of 2028.
Phase 2 TibuSHIELD (HS) on track for topline data Q4 2026; TibuSURE (SSc) data expected H1 2027.
Completed $144M public offering in February 2026; appointed new CEO and two board members.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Zura Bio Ltd reported first quarter ended March 31, 2026 results: net income $24.2 million, or $0.22 per share, EPS $0.22 per share.

Period: first quarter ended March 31, 2026
Net income: $24.2 million, or $0.22 per share
EPS: $0.22 per share
Result: reported results

Exact text from the filing

Net loss for the first quarter of 2026 was $24.2 million, or $0.22 per share

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Zura Bio Ltd filing history →

Source: SEC EDGAR

accession 0001628280-26-031701

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.